Genomic Testing Can Help Identify Patients at Heightened Risk for Esophageal Cancer
Endoscopic Samples Show Precancerous Genomic Changes in Barrett’s Esophagus, According to Report in The Journal of Molecular Diagnostics

Philadelphia, PA, June 8, 2015 – Barrett’s esophagus (BE) develops in a subset of patients with gastroesophageal reflux disease (GERD) and can increase the risk of developing cancer of the esophagus. Although periodic surveillance for cancer is recommended for BE patients, these examinations may fail to identify pre-cancerous dysplasia and early cancers. A report in The Journal of Molecular Diagnostics describes a test using next-generation sequencing (NGS) to detect genomic mutations in precancerous esophageal tissue, which may improve cancer surveillance and early detection in patients with BE.

“BE results from injury of the esophageal mucosa associated with gastroesophageal reflux, which leads to inflammation (esophagitis) and eventually BE,” explained Antonia R. Sepulveda, MD, PhD, Professor of Pathology and Cell Biology, Vice Chair for Translational Research, and Director of the Division of Gastrointestinal Pathology at Columbia University College of Physicians and Surgeons, New York, NY. In the normal esophagus, the tissue lining is made of flat squamous cells that appear pearly white and smooth during endoscopy. In patients with BE, the cells lining the esophagus appear more like cells characteristic of the small intestine (known as specialized intestinal metaplasia). As BE progresses, cells may become more disordered and disorganized, sequentially changing to low-grade dysplasia, high-grade dysplasia (HGD), and eventually esophageal adenocarcinoma (EAC).

Pathology evaluation of biopsy samples is the gold standard for detection of dysplasia in BE. Molecular testing of BE has not entered clinical practice in part due to limitations of molecular testing methods requiring fresh or frozen tissue samples and lack of sensitivity to detect low-level mutations in precancerous samples.
Dr. Sepulveda and colleagues tested readily-available formalin-fixed, paraffin-embedded (FFPE) tissue taken from esophageal biopsies or endoscopic mucosal resections. Using NGS methods, the researchers analyzed FFPE tissue samples from 13 "non-progressors" (patients with BE who never manifested dysplasia or EAC during at least two years of monitoring), 15 "progressors" (patients who developed HGD or EAC), and control samples showing no evidence of Barrett’s intestinal metaplasia. The researchers found that progressors had mutations in 75% (6/8) of cases compared to 0% in non-progressors. The tumor suppressor TP53 was the most commonly mutated gene in the BE progressor group. Mutations were also found in the APC and CDKN2A tumor suppressor genes.

“The ability to detect mutations in non-neoplastic mucosa, quantitatively and with high detection sensitivity, makes it possible to use NGS mutational testing in the early detection and surveillance of patients who develop BE,” noted Dr. Sepulveda.

BE is considered one of the most significant risk factors for EAC. Compared with the general population, patients with BE have more than an 11-fold increased risk for EAC. Although EAC is a relatively rare cancer, it is the tenth leading cause of cancer death in the United States. Between 2005 and 2011, about 18% of EAC patients survived for five years. However, because earlier cancer detection is associated with longer survival, there is a great need for detecting cancer early and finding biomarkers that can help predict patients at greatest risk.

NOTES FOR EDITORS


Full text of this study is available to credentialed journalists upon request; contact Eileen Leahy at 732-238-3628 or jmdmedia@elsevier.com. Journalists wishing to interview the authors of the study should contact Karin Eskenazi, Director, Media Relations, Columbia University Medical Center, at 212-342-0508 or ket2116@columbia.edu.

This research was supported in part by a CTSI-PATS pilot grant from the Institute for Translational Medicine and Therapeutics, University of Pennsylvania, the Department of Pathology and Cell Biology, Columbia University, pilot award 5U54CA163004 from the BETRNET consortium, and NIH grants UL1TR000005, R01EB016657, and R01CA185363.

ABOUT THE JOURNAL OF MOLECULAR DIAGNOSTICS

The Journal of Molecular Diagnostics, (http://jmd.amipathol.org), the official publication of the Association for Molecular Pathology, co-owned by the American Society for Investigative Pathology, and published by Elsevier, Inc., seeks to publish high quality original papers on scientific advances in the translation and validation of molecular discoveries in medicine into the clinical diagnostic setting, and the description and application of technological advances in the field of molecular diagnostic medicine. The editors welcome for review articles that contain: novel discoveries or clinicopathologic correlations including studies in oncology, infectious diseases, inherited diseases, predisposition to disease, or the description of polymorphisms linked to disease states or normal variations; the application of diagnostic
methodologies in clinical trials; or the development of new or improved molecular methods for diagnosis or monitoring of disease or disease predisposition.

*The Journal of Molecular Diagnostics,* with an Impact Factor of 3.955, ranks 13th among 76 journals in Pathology, according to 2013 *Journal Citation Reports*® Thomson Reuters, 2014.

**ABOUT ELSEVIER**
Elsevier ([www.elsevier.com](http://www.elsevier.com)) is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect ([www.sciencedirect.com](http://www.sciencedirect.com)), Scopus ([www.scopus.com](http://www.scopus.com)), Elsevier Research Intelligence ([www.elsevier.com/research-intelligence](http://www.elsevier.com/research-intelligence)), and ClinicalKey ([www.clinicalkey.com](http://www.clinicalkey.com)) — and publishes over 2,500 journals, including *The Lancet* ([www.thelancet.com](http://www.thelancet.com)) and *Cell* ([www.cell.com](http://www.cell.com)), and more than 33,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group plc ([www.relxgroup.com](http://www.relxgroup.com)), a world-leading provider of information solutions for professional customers across industries. [www.elsevier.com](http://www.elsevier.com)